Traws Pharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
TRAW$0.24+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · September 30, · · December 31, · | |||||||
| · · 2025 · · 2024 · | |||||||
| Assets · · · · · · | |||||||
| Current assets: | | | | | | | |
| Cash and cash equivalents | | $6,420,000 | | $21,338,000 | | ||
| Tax incentive and other receivables | | 1,991,000 | | 1,765,000 | | ||
| Prepaid expenses and other assets | | 1,214,000 | | 1,848,000 | | ||
| Total current assets | | 9,625,000 | | 24,951,000 | | ||
| Property and equipment, net | | 7,000 | | 10,000 | | ||
| Intangible assets, net | | | 2,571,000 | | | — | |
| Other assets | | 240,000 | | 1,000 | | ||
| Total assets | | $12,443,000 | | $24,962,000 | | ||
| Liabilities and stockholders’ equity (deficit) | | | | | | | |
| Current liabilities: | | | | | | | |
| Accounts payable | | $5,105,000 | | $8,186,000 | | ||
| Accrued expenses and other liabilities | | 2,782,000 | | 3,121,000 | | ||
| Deferred revenue | | — | | 226,000 | | ||
| Total current liabilities | | 7,887,000 | | 11,533,000 | | ||
| Deferred revenue, non-current | | — | | 2,565,000 | | ||
| Warrant liabilities | | 11,000 | | 42,494,000 | | ||
| Total liabilities | | 7,898,000 | | | 56,592,000 | | |
| | | | | | | | |
| Commitments and contingencies (Note 6) | | | | | | | |
| | | | | | | | |
| Stockholders’ equity (deficit): | | | | | | | |
| Series C Preferred stock, $0.01 par value, 5,000,000 shares authorized, 7,440 shares issued, 6,737 and 7,398 shares outstanding at September 30, 2025 and December 31, 2024, respectively | | — | | — | | ||
| Common stock, $0.01 par value, 250,000,000 shares authorized, 7,131,151 and 3,650,731 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | | 71,000 | | 36,000 | | ||
| Additional paid-in capital | | 637,009,000 | | 617,530,000 | | ||
| Accumulated deficit | | (632,541,000) | | (649,154,000) | | ||
| Accumulated other comprehensive income (loss) | | 6,000 | | (42,000) | | ||
| Total stockholders’ equity (deficit) | | 4,545,000 | | (31,630,000) | | ||
| Total liabilities and stockholders’ equity (deficit) | | $12,443,000 | | $24,962,000 | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.